Spectrum Pharma (SPPI) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update
August 3, 2017 4:02 PM EDTROLONTIS (eflapegrastim): BLA filing expected next year. Enrollment completed in registrational ADVANCE Study under a Special Protocol Assessment (SPA) with the FDA. Topline results expected in Q1 2018. A second smaller study RECOVER is enrolling patients in EU and U.S. Enrollment completion expected in Q1 2018. Poziotinib: Interim results are expected before year end from an ongoing Phase 2 study in non-small cell lung cancer patients with exon 20 insertion mutations in... More
